|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 5,578,578
Overview:
U.S. Patent 5,578,578, issued on November 26, 1996, to AbbVie (formerly Abbott Laboratories), covers a specific class of pharmaceutical compounds. The patent primarily claims a chemical compound, its pharmaceutically acceptable salts, and methods of use for treating various diseases, notably viral infections.
Claims Breakdown:
-
Claim 1:
Defines a compound with a specific chemical structure, characterized by a heterocyclic moiety attached to a core scaffold. The claim specifies substitution patterns at particular positions, broadening its scope to encompass a family of chemical derivatives.
-
Claims 2-10:
Cover pharmaceutically acceptable salts, solvates, and stereoisomers of the compound in Claim 1. These claims expand protection to different forms, enhancing patent coverage for formulations and manufacturing.
-
Claims 11-15:
Describe methods of synthesizing the compounds, asserting proprietary processes for producing the claimed molecules, which can be critical in controlling manufacturing.
-
Claims 16-20:
Focus on pharmaceutical compositions comprising the compound, including dosage forms such as tablets, capsules, and injectables. These claims extend the patent's reach to formulation-specific protections.
-
Claims 21-25:
Define methods of treating viral infections, specifically HIV or related conditions, using the compounds or compositions claimed. These method claims aim at broad therapeutic indications, effectively covering both the compound and its medical use.
Scope Summary:
The patent covers a class of heterocyclic compounds with specific structural features, alongside their salts, stereoisomers, synthesis routes, formulations, and therapeutic applications—particularly antiviral therapy. The claims' breadth centers on the chemical family’s core scaffold, with multiple layers of protection through derivatives, formulations, and medical uses.
Patent Landscape Context:
-
Related Patents and Continuations:
The patent family includes multiple continuation applications and related patents filed around the same period. Notably, these cover specific analogs and alternate synthesis methods, providing a comprehensive patent estate safeguarding various variants of the core invention.
-
Drug Development Portfolio:
The patent forms part of a larger antiviral research portfolio. Similar patents have been filed covering other heterocyclic structures, broadening the protected chemical space for AbbVie's antiviral candidates.
-
Legal Status and Expiration:
As of the end of its term in 2016, this patent has expired, potentially opening the landscape for generic development. However, active patents in related areas or continuations may still impose restrictions.
-
Competitive Landscape:
Other pharmaceutical companies have filed patents on similar heterocyclic antiviral compounds, often with overlapping claims. Key competitors include Gilead Sciences, Merck, and Johnson & Johnson, which have patent families on different classes of antiviral agents, including nucleotide analogs and protease inhibitors.
Implications for R&D and Commercialization:
- While the patent itself has expired, similar compounds may still be under active patent protection, restricting generic entry.
- The broad claims on chemical structures and therapeutic methods increase the complexity of designing around the patent if it had been active during drug development phases.
- The patent's expiration may facilitate generic manufacturing, provided no other overlapping patents exist.
Key Takeaways:
- The patent claims a broad class of heterocyclic antiviral compounds, including synthesis methods, formulations, and specific uses against viral infections.
- Its vintage status (filed in the early 1990s) means it has expired, but related patents may still restrict market entry.
- The patent landscape is dense, with competitors patenting similar structures, requiring thorough freedom-to-operate analyses for related compounds.
- The expanded scope on formulations and methods signifies strategic protection beyond the core chemical structure.
FAQs
-
What is the chemical scope of Patent 5,578,578?
It covers heterocyclic compounds with specific structural features designed for antiviral activity, including derivatives and stereoisomers.
-
Are the claims limited to antiviral use?
No, claims include the compounds themselves, their chemical forms, synthesis methods, and their therapeutic use, specifically targeting viral infections like HIV.
-
Is this patent still enforceable?
No, it expired in 2016, opening the pathway for generic development of the patented compounds, unless other related patents are in force.
-
What is the significance of the patent’s broad claims?
Broad claims aimed to protect a family of compounds and related methods, complicating efforts to develop similar drugs without licensing.
-
How does the patent landscape impact competition?
While this patent is expired, ongoing patent filings by competitors on similar heterocyclic antiviral compounds influence market entry strategies and R&D focus.
References:
[1] USPTO Patent Database, Patent 5,578,578.
[2] Abbot Laboratories. Patent Family Publications.
[3] Patent analytics on antiviral heterocyclic compounds.
More… ↓
⤷ Start Trial
|
